Ftse Mib
33.220,31
-0,29%
DAX
18.067,91
-0,31%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
64.818,95
-0,23%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Eledon Pharmaceuticals Inc (ELDN) Eledon Pharmaceuticals Inc (ELDN) Notizie

ELDN

Eledon Pharmaceuticals (ELDN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELDN
DataOraFonteTitoloSimboloCompagnia
14/06/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
06/06/202422:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELDNEledon Pharmaceuticals Inc
06/06/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELDNEledon Pharmaceuticals Inc
03/06/202422:01GlobeNewswire Inc.Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationNASDAQ:ELDNEledon Pharmaceuticals Inc
30/05/202422:25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ELDNEledon Pharmaceuticals Inc
30/05/202422:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ELDNEledon Pharmaceuticals Inc
24/05/202422:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELDNEledon Pharmaceuticals Inc
15/05/202413:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
13/05/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
09/05/202413:30GlobeNewswire Inc.Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
09/05/202413:00GlobeNewswire Inc.Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202413:05GlobeNewswire Inc.Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202413:00GlobeNewswire Inc.Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementNASDAQ:ELDNEledon Pharmaceuticals Inc
28/03/202421:01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
25/03/202421:56GlobeNewswire Inc.Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
21/03/202415:31GlobeNewswire Inc.Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanNASDAQ:ELDNEledon Pharmaceuticals Inc
14/02/202421:35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELDNEledon Pharmaceuticals Inc
14/02/202421:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELDNEledon Pharmaceuticals Inc
14/02/202401:01GlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
04/01/202422:40GlobeNewswire Inc.Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookNASDAQ:ELDNEledon Pharmaceuticals Inc
29/11/202322:05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
09/11/202322:01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
08/11/202322:05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
02/11/202314:05GlobeNewswire Inc.Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationNASDAQ:ELDNEledon Pharmaceuticals Inc
23/10/202313:00GlobeNewswire Inc.Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerNASDAQ:ELDNEledon Pharmaceuticals Inc
13/10/202313:00GlobeNewswire Inc.Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual MeetingNASDAQ:ELDNEledon Pharmaceuticals Inc
02/10/202323:51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
02/10/202313:00GlobeNewswire Inc.Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of DirectorsNASDAQ:ELDNEledon Pharmaceuticals Inc
25/09/202313:00GlobeNewswire Inc.Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a HumanNASDAQ:ELDNEledon Pharmaceuticals Inc
20/09/202322:05GlobeNewswire Inc.Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELDN

La tua Cronologia

EU
FR0010302794
Minotfccbfrn Bonds
BIT
P1VM43
NLBNPIT1VM43 20351221 88...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network